Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.

The reported higher risk of maternal and fetal complications in women with myeloproliferative neoplasms (MPN) poses challenge during pregnancy. A national prospective study of maternal and fetal outcomes of pregnant women with a diagnosis of MPN was undertaken via the United Kingdom Obstetric Surveillance System between January 2010 and December 2012. Fifty-eight women with a diagnosis of MPN were identified; 47 (81%) essential thrombocythaemia, five (9%) polycythaemia vera, five (9%) myelofibrosis and one (2%) MPN-unclassified.

Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes.

Objective: To determine whether women with persistent aPL (>12 weeks apart on at least two separate occasions) without a history of thrombosis or adverse pregnancy outcome had the same adverse pregnancy outcomes as those with obstetric APS or unmatched controls.

Methods: This was a case-control study between 2005 and 2011 where we identified 73 women with persistent aPL and coincidentally the same number with obstetric APS. Unmatched controls were identified from low-risk clinics (ratio 1:4).

Thromboembolic disorders in obstetrics.

Thromboembolic disorders remain a leading cause of maternal mortality in the developed world. The halving of the number of deaths from thromboembolic disorders in the last Confidential Enquiry provides further proof that they are largely preventable. A formal assessment of risk factors (e.